MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC
Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
The MASPAC trial investigates the added benefit of MR-guided adaptive SBRT of the primary
tumor embedded between standard chemotherapy cycles for pain control and prevention of pain
in patients with metastatic PDAC (mPDAC).